OMNIPAQUE 300mg I/ml price in UAE

Overview

Welcome to Dwaey, specifically on OMNIPAQUE 300mg I/ml Injection/Solution for page.
This medicine contains an important and useful components, as it consists of Iohexol.
OMNIPAQUE 300mg I/ml is available in the market in concentration 647mg/ml and in the form of Injection/Solution for.

GE HEALTHCARE AS is the producer of OMNIPAQUE 300mg I/ml and it is imported from NORWAY, The most popular alternatives of OMNIPAQUE 300mg I/ml are listed downward .

Mode Of Action

Allows for radiographic visualization through the opacification of vessels and anatomical structures in the path of flow of the contrast media.

Indication

Radiographic contrast medium for diagnostic procedures

Precaution

Asthma or a history of allergies (risk of anaphylactoid reactions is increased); compromised blood-brain barrier (severe neurotoxicity after intrathecal use); epilepsy and brain tumour (higher risk of convulsions); severe hepatic or renal impairment, diabetics with renal impairment, dehydration and others who may be at increased risk of renal failure; multiple myeloma (dehydration from use may cause precipitation of protein in the renal tubules, leading to anuria and fatal renal failure); severe hypertension; advanced cardiac disease; phaeochromocytoma; sickle-cell disease; hyperthyroidism; debilitated, severely ill, very old, or very young patients; occlusive vascular disease. Special care to ensure that 140 and 350 mg iodine/ml solutions are not given intrathecally. Adequate resuscitative facilities should be available when radiographic procedures are undertaken, and patients should be kept under observation for a suitable period after the procedure. Lactation: Not known; not recommended

Side Effects

Flushing or a sensation of heat; pain
extravasation
thrombophlebitis at the inj site; nausea
vomiting
headache
and dizziness; urticaria
pruritus
pallor
sweating
metallic taste
weakness
coughing
rhinitis
sneezing
lachrymation
visual disturbances; hypotension
tachycardia
bradycardia
transient ECG abnormalities
haemodynamic disturbances; dyspnoea
bronchospasm
angioedema
severe urticaria; convulsions
paraesthesia
paralysis; acute renal failure; thromboembolism
disseminated intravascular coagulation
thrombocytopenia; hyperthyroidism
thyroid storm thyrotoxicosis. Potentially Fatal: Profound hypotension
pulmonary oedema
respiratory arrest
ventricular fibrillation
circulatory failure
cardiac arrest
coma.

Contra indication

Procedure-specific. Intrathecal: Myelography in significant local or systemic infection where bacteremia is likely; concurrent use with corticosteroids; repeat myelography in the event of technical failure (risk of overdosage). Hysterosalpingography: During menstrual period or when menstrual flow in imminent; presence of infection; pregnancy, 6 mth after termination of pregnancy or 30 days after conization or curettage.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.